Eli Lilly & Co. (LLY)

108.25
0.39 0.36
NYSE : Health Technology
Prev Close 108.64
Open 108.87
Day Low/High 107.78 / 109.00
52 Wk Low/High 104.17 / 132.13
Volume 1.46M
Avg Volume 3.39M
Exchange NYSE
Shares Outstanding 965.43M
Market Cap 104.71B
EPS 3.10
P/E Ratio 25.76
Div & Yield 2.58 (2.28%)

Latest News

Lilly Announces Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint Of Overall Survival

Lilly Announces Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint Of Overall Survival

INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with...

Lilly Presents Positive Results For Taltz® (ixekizumab) In Pediatric Patients With Moderate To Severe Plaque Psoriasis At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Lilly Presents Positive Results For Taltz® (ixekizumab) In Pediatric Patients With Moderate To Severe Plaque Psoriasis At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Taltz is the first and only IL-17A inhibitor with published clinical trial results in pediatric patients with moderate to severe plaque psoriasis

Lilly's REYVOW™ (lasmiditan), The First And Only Medicine In A New Class Of Acute Treatment For Migraine, Receives FDA Approval

Lilly's REYVOW™ (lasmiditan), The First And Only Medicine In A New Class Of Acute Treatment For Migraine, Receives FDA Approval

- The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades

Lilly To Unveil New Data For The Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Lilly To Unveil New Data For The Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world

Lilly's CYRAMZA® (ramucirumab) Phase 3 Data In First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published In The Lancet Oncology

Lilly's CYRAMZA® (ramucirumab) Phase 3 Data In First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published In The Lancet Oncology

CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations

Lilly Announces Voluntary Delisting From Euronext Paris

Lilly Announces Voluntary Delisting From Euronext Paris

INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) ("Lilly Shares") from Euronext Paris due to the very low trading volume, costs and...

New Head-to-Head Data Show Taltz® (ixekizumab) Superiority Versus TREMFYA® (guselkumab) In People With Moderate To Severe Plaque Psoriasis

New Head-to-Head Data Show Taltz® (ixekizumab) Superiority Versus TREMFYA® (guselkumab) In People With Moderate To Severe Plaque Psoriasis

-Taltz met the primary endpoint of the IXORA-R study, with 41.3 percent of patients taking Taltz achieving complete skin clearance as measured by PASI 100 at Week 12 versus 24.9 percent of patients taking TREMFYA

Lilly Confirms Date And Conference Call For Third-Quarter 2019 Financial Results Announcement

Lilly Confirms Date And Conference Call For Third-Quarter 2019 Financial Results Announcement

INDIANAPOLIS, Oct. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019.

Lilly Announces Positive Registrational Data For Selpercatinib (LOXO-292) In Heavily Pretreated RET-Altered Thyroid Cancers

Lilly Announces Positive Registrational Data For Selpercatinib (LOXO-292) In Heavily Pretreated RET-Altered Thyroid Cancers

- LIBRETTO-001 is the largest trial ever reported in RET-altered cancer patients

Verzenio® (abemaciclib) Significantly Extends Life By A Median Of 9.4 Months For Women With HR , HER2- Advanced Breast Cancer In MONARCH 2 Study

Verzenio® (abemaciclib) Significantly Extends Life By A Median Of 9.4 Months For Women With HR , HER2- Advanced Breast Cancer In MONARCH 2 Study

Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone - MONARCH 2 showed statistically significant results for women whose disease progressed following endocrine therapy

Lilly Oncology To Present Robust Data Across Its Growing Portfolio At ESMO 2019

Lilly Oncology To Present Robust Data Across Its Growing Portfolio At ESMO 2019

Verzenio® (abemaciclib) Phase 3 data included in ESMO Presidential Symposium and Official Press Program: Positive overall survival results to be presented from MONARCH 2, evaluating Verzenio with fulvestrant for the treatment of women with HR+, HER2- advanced breast cancer whose cancer grew or spread following endocrine therapy

CHMP Issues Positive Opinion To Expand Trulicity® (dulaglutide) Label To Include Results From REWIND Cardiovascular Outcomes Trial

CHMP Issues Positive Opinion To Expand Trulicity® (dulaglutide) Label To Include Results From REWIND Cardiovascular Outcomes Trial

INDIANAPOLIS, Sept. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an update to the Trulicity®...

Lilly Announces Webcast To Discuss ESMO 2019 Presentations

Lilly Announces Webcast To Discuss ESMO 2019 Presentations

INDIANAPOLIS, Sept. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona,...

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Tech Stocks Lag, Health Care Shakes Up and Apple's in TV

Tuesday is a big day as the rotation in the markets continues -- putting the likes of Salesforce.com on sale; pharma gets jitters over political climate; and Apple aims at Netflix and co.

Eli Lilly's Must-Hold Level on Drug-Data Pullback

Eli Lilly's Must-Hold Level on Drug-Data Pullback

Eli Lilly stock is falling on the day after releasing clinical trial data. Here's the must-hold spot for LLY stock now.

Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

Lilly acquired the drug as part of its $8 billion acquisition of Loxo Oncology.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Lilly's Pain Clinical Trial Protocol Selected For FDA Complex Innovative Trial Designs Pilot Meeting Program

Lilly's Pain Clinical Trial Protocol Selected For FDA Complex Innovative Trial Designs Pilot Meeting Program

INDIANAPOLIS, Sept. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.

Lilly To Participate In Morgan Stanley Global Healthcare Conference

Lilly To Participate In Morgan Stanley Global Healthcare Conference

INDIANAPOLIS, Sept. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019.

Let's Make a Deal: Cramer's 'Mad Money' Recap (Monday 8/26/19)

Let's Make a Deal: Cramer's 'Mad Money' Recap (Monday 8/26/19)

Jim Cramer says a quick trade deal is unlikely, and investors need to filter out the day-to-day noise.

Lilly Receives U.S. FDA Approval For Taltz® (ixekizumab) For The Treatment Of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Lilly Receives U.S. FDA Approval For Taltz® (ixekizumab) For The Treatment Of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

INDIANAPOLIS, Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be...

Arbitration Panel Rules In Favor Of Lilly In Complaint Filed By Adocia

Arbitration Panel Rules In Favor Of Lilly In Complaint Filed By Adocia

INDIANAPOLIS, Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.

Lilly Announces Webcast To Discuss World Conference On Lung Cancer Presentation

Lilly Announces Webcast To Discuss World Conference On Lung Cancer Presentation

INDIANAPOLIS, Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20 th meeting of the International Association for the...

Lilly Launches Open Innovation Challenge To Help Transform Inflammatory Bowel Disease (IBD) Care Through Digital Health

Lilly Launches Open Innovation Challenge To Help Transform Inflammatory Bowel Disease (IBD) Care Through Digital Health

INDIANAPOLIS, Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.

Lilly Announces Superiority Of Taltz® (ixekizumab) Versus TREMFYA® (guselkumab) In Delivering Total Skin Clearance At Week 12 In Topline Results From Head-to-Head (IXORA-R) Trial In People Living With Moderate To Severe Plaque Psoriasis

Lilly Announces Superiority Of Taltz® (ixekizumab) Versus TREMFYA® (guselkumab) In Delivering Total Skin Clearance At Week 12 In Topline Results From Head-to-Head (IXORA-R) Trial In People Living With Moderate To Severe Plaque Psoriasis

- IXORA-R is the first Phase 4 head-to-head study comparing efficacy between an IL-17A inhibitor and an IL-23/p19 inhibitor using PASI 100 as the primary endpoint -

TheStreet Quant Rating: C+ (Hold)